Bone Biologics (BBLGW) Total Current Liabilities (2013 - 2026)

Bone Biologics (BBLGW) has reported Total Current Liabilities for 14 consecutive years, with $512018.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 26.07% year-over-year to $512018.0 in Q2 2026; TTM through Jun 2026 was $512018.0, a 26.07% increase from a year earlier, with the FY2025 full-year figure at $418587.0, up 10.82% from the prior year.
• Total Current Liabilities was $512018.0 for Q2 2026 at Bone Biologics, up from $418587.0 in the prior quarter.
• Over five years, Total Current Liabilities peaked at $4.0 million in Q1 2023 and troughed at $164626.0 in Q1 2024.
• A 5-year average of $966186.4 and a median of $412364.5 in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 2450.25% in 2022 and plunged 95.9% in 2024, its largest moves.
• Over 5 years, Total Current Liabilities stood at $2.5 million in 2022, then tumbled by 67.37% to $831402.0 in 2023, then slumped by 54.57% to $377712.0 in 2024, then grew by 10.82% to $418587.0 in 2025, then advanced by 22.32% to $512018.0 in 2026.
• The last three Total Current Liabilities figures came in at $512018.0 (Q2 2026), $418587.0 (Q4 2025), and $334282.0 (Q3 2025), per Business Quant data.